Strategic partnerships Orbit Discovery actively pursues collaborations with industry players (Orano Med SAS, Evergreen Discovery, Evergreen Theragnostics, SanegeneBio) to develop radiopharmaceuticals and targeted peptide therapies, indicating strong sales opportunities in co-development and technology licensing for radiopharmaceutical and peptide targeting applications.

Radiopharma focus The company’s emphasis on peptide receptor radionuclide therapies and Pb Targeted Alpha Therapy suggests a demand for peptide leads and screening services tailored to radiopharmaceutical development, offering potential upsell of peptide discovery platforms and related consulting.

In-house pipeline With a pipeline of novel targets and an in-house program alongside academia and industry collaborations, Orbit presents opportunities to license or co-develop novel peptide leads and expand into adjacent targets for cancer therapies and cargo delivery platforms.

Clinical relevance Orbit’s ability to address cell-based targets in relevant contexts positions their peptide leads as versatile starting points for peptide, peptidomimetic, and small molecule therapeutics, enabling partnerships to tailor leads for client-specific radiopharmaceuticals or cell-targeting therapies.

Funding & growth Recent grants and funding to expand microfluidics screening capabilities indicate growing technical capacity and scalability, presenting a selling point for customers seeking robust screening, high-throughput discovery, and faster development timelines.